MGTX
MeiraGTx Holdings·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 4
Bearish signal 3
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Growth
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MGTX
Meiragtx Holdings Plc
A US-based clinical-stage gene therapy company developing treatments for rare genetic disorders and ophthalmic diseases
655 Third Avenue
Suite 1115
New York
NY 10017
Develops genetic medicines.
MeiraGTx Holdings plc was incorporated under the laws of the Cayman Islands on May 1, 2018. The company is a vertically integrated clinical-stage genetic medicine company with extensive late-stage clinical programs, including xerostomia, Parkinson's disease and AIPL1 related retinal dystrophy. The company's clinical programs use targeted, topical, low-dose genetic drugs to treat hereditary diseases and more common diseases with serious unmet needs.
Company Financials
EPS
MGTX has released its 2026 Q2 earnings. EPS was reported at -1.71, versus the expected -0.46, missing expectations. The chart below visualizes how MGTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MGTX has released its 2026 Q2 earnings report, with revenue of 321.43M, reflecting a YoY change of 8608.59%, and net profit of 160.67M, showing a YoY change of 514.15%. The Sankey diagram below clearly presents MGTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
